Montané E, Arellano AL, Sanz Y, Roca J, Farré M. Drug-related deaths in hospital inpatients: a retrospective cohort study. Br J Clin Pharmacol 2017;84:1. [Ref.ID 102184]

Ruggiero A, Ferrara P, Attinà G, Rizzo D, Riccardi C. Renal toxicity and chemotherapy in children with cancer. Br J Clin Pharmacol 2017;83:2605-14. [Ref.ID 102170]

Khan Q, Ismail M, Haider I, Haq IU, Noor S. QT interval prolongation in hospitalized patients on cardiology wards: a prospective observational study. Eur J Clin Pharmacol 2017;73:1511-8. [Ref.ID 102127]

Alharbi FF, Souverein PC, de Groot MCH, Blom MT, de Boer A, Klungel OH, Tan HL. The impact of serum potassium-influencing antihypertensive drugs on the risk of out-of-hospital cardiac arrest: a case–control study. Br J Clin Pharmacol 2017;83:2541-8. [Ref.ID 102115]

Anónimo. FDA announces list of off-patent drugs with no competition. DIA Daily 2017:1. [Ref.ID 101658]

Chan WY, Clark AB, Wilson AM, Loke YK, on behalf of the TIPAC investigators. The effect of co-trimoxazole on serum potassium concentration: safety evaluation of a randomized controlled trial. Br J Clin Pharmacol 2017;83:agosto. [Ref.ID 101544]

Anónimo. Spironolactone - potion or poison?. Drug Ther Bull 2017;55:13. [Ref.ID 101402]

Anónimo. AstraZeneca says FDA has accepted new application for hyperkalaemia treatment. DIA Daily 2016:4. [Ref.ID 100847]

Williamson JD, Supiano MA, Applegate WB, Berlowitz DR, Campbell RC, Chertow GM, Fine LJ, Haley WE, Hawfield AT, Ix JH, Kitzman DW, Kostis JB, Krousel-Wood MA, Launer LJ, Oparil S, Rodríguez CJ, Roumie CL, Shorr RI, Sink KM, Wadley VG, Whelton PK, Whittle J, Woolard NF, Wright Jr JT, Pajewski NM, for the SPRINT Research Group. Intensive vs standard blood pressure control and cardiovascular disease outcomes in adults aged =75 years: a randomized clinical trial. JAMA 2016;315:2673-82. [Ref.ID 100474]

Griebeler ML, Kearns AE, Ryu E, Thapa P, Hathcock MA, Melton LJ, Wermers RA. Thiazide-associated hypercalcemia: incidence and association with primary hyperparathyroidism over two decades. J Clin Endocrinol Metab 2016;101:1166-73. [Ref.ID 100079]

Schoenfeld AJ, Grady D. Adverse effects associated with proton pump inhibitors. JAMA Intern Med 2016;176:febrero. [Ref.ID 99958]

Drazen JM, Morrissey S, Campion EW, Jarcho JA. A SPRINT to the finish. N Engl J Med 2015;373:2174-5. [Ref.ID 99776]

Sternlicht H, Bakris GL. Spironolactone for resistant hypertension—hard to resist?. Lancet 2015;386:2032-4. [Ref.ID 99769]

Cheungpasitporn W, Thongprayoon C, Kittanamongkolchai W, Srivali N, Edmonds PJ, Ungprasert P, O'Corragain OA, Korpaisarn S, Erickson SB. Proton pump inhibitors linked to hypomagnesemia: a systematic review and meta-analysis of observational studies. Renal Failure 2015;37:1237-41. [Ref.ID 99742]

Cheungpasitporn W, Thongprayoon C, Mao MA, Srivali N, Ungprasert P, Varothai N, Sanguankeo A, Kittanamongkolchai W, Erickson SB. Hypomagnesaemia linked to depression: a systematic review and meta-analysis. Internal Medicine Journal 2015;45:436-40. [Ref.ID 99741]

Anónimo. Hyponatrémies d'origine médicamenteuse. Prescrire 2015;35:666-71. [Ref.ID 99717]

The SPRINT Research Group. A randomized trial of intensive versus standard blood-pressure control. N Engl J Med 2015;373:2013-6. [Ref.ID 99661]

Kelley KJ. Oral hyperkalemia drug approved. Journal Watch 2015:23 de octubre. [Ref.ID 99572]

Williams B, MacDonald TM, Morant S, Webb DJ, Sever P, McInnes G, Ford I, Cruickshank JK, Caulfield MJ, Salsbury J, Mackenzie I, Padmanabhan S, Brown MJ, for The British Hypertension Society's PATHWAY Studies Group. Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial. Lancet 2015;386:2059-68. [Ref.ID 99524]

Anónimo. Aliskirène: hyponatrémies. Prescrire 2015;35:506. [Ref.ID 99439]